SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'total_freecashflow' CCEL (Cryo-Cell International) Free Cash Flow
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Free Cash Flow

Cryo-Cell International (Cryo-Cell International) Free Cash Flow

: $-0.80 Mil (TTM As of Feb. 2024)
View and export this data going back to . Start your Free Trial

Cryo-Cell International's total free cash flow for the months ended in Feb. 2024 was $-0.82 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.80 Mil.

Cryo-Cell International's Free Cash Flow per Share for the months ended in Feb. 2024 was $-0.10. Its free cash flow per share for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.10.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -46.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.

During the past 13 years, Cryo-Cell International's highest 3-Year average Free Cash Flow per Share Growth Rate was 199.60% per year. The lowest was -80.30% per year. And the median was 9.05% per year.

Cryo-Cell International Free Cash Flow Historical Data

The historical data trend for Cryo-Cell International's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryo-Cell International Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Free Cash Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.63 8.02 0.98 -8.60 1.28

Cryo-Cell International Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Free Cash Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.27 0.13 -1.48 1.36 -0.82

Cryo-Cell International Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Cryo-Cell International's Free Cash Flow for the fiscal year that ended in Nov. 2023 is calculated as

Free Cash Flow (A: Nov. 2023 )=Cash Flow from Operations+Capital Expenditure
=8.92+-7.639
=1.28

Cryo-Cell International's Free Cash Flow for the quarter that ended in Feb. 2024 is calculated as

Free Cash Flow (Q: Feb. 2024 )=Cash Flow from Operations+Capital Expenditure
=-0.357+-0.458
=-0.82

Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International  (AMEX:CCEL) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Feb24, Cryo-Cell International's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Feb24)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0.21961905/5.2+0.0242
=6.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.

Cryo-Cell International Free Cash Flow Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryo-Cell International (Cryo-Cell International) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Free Cash Flow
Comparable Companies
AONC PHCI CCM ATIP AMS HLYK AIH VLXC SYRA NVOS HCA SAU:4013 SZSE:300015 XTER:FRE BKK:BDMS UHS DVA ADX:PUREHEALTH BSP:RDOR3 XTER:FME
Traded in Other Exchanges
ZCY:Germany
Address
700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Website
https://www.cryo-cell.com
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group functions through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.
Executives
David Portnoy director, officer: Co-Chief Executive Officer C/O FOCUS FINANCIAL GROUP, 61 HARBOUR WAY, BAL HARBOUR FL 33154
George Gaines director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Jonathan H. Wheeler director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Brian L. Sheehy director 415 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Mark L. Portnoy director, officer: Co-Chief Executive Officer 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Harold D. Berger director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Arthur Ellis director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Mary J Nyberg 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Cdmj Nyberg Family Trust 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Jill M Taymans officer: VP, Finance, CFO
Oleg Mikulinsky officer: Chief Information Officer 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Anthony Atala director 700 BROOKER CREEK BOULEVARD, OLDSMAR FL 34677
Scott G Christian director
Sung Won Sohn director 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Michael W. Cho director C/O IOWA STATE UNIVERSITY, 1600 S. 16TH STREET, AMES IA 50011-1250